Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.

Saved in:
Bibliographic Details
Title: Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.
Authors: Jones NK; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom., Rivett L; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United Kingdom., Seaman S; Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom., Samworth RJ; Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, Cambridge, United Kingdom., Warne B; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom.; Department of Medicine, University of Cambridge, Cambridge, United Kingdom., Workman C; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom., Ferris M; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom., Wright J; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom., Quinnell N; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom., Shaw A; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom., Goodfellow IG; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom., Lehner PJ; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom.; Department of Medicine, University of Cambridge, Cambridge, United Kingdom., Howes R; Cambridge COVID-19 Testing Centre and AstraZeneca, Anne McLaren Building, Cambridge, United Kingdom., Wright G; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United Kingdom., Matheson NJ; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom.; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.; NHS Blood and Transplant, Cambridge, United Kingdom., Weekes MP; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Corporate Authors: Cambridge COVID-19 Collaboration; Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom.; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
Source: ELife [Elife] 2021 Apr 08; Vol. 10. Date of Electronic Publication: 2021 Apr 08.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2050-084X
DOI:10.7554/eLife.68808